H.C. Wainwright initiated coverage of PDS Biotechnology (NASDAQ:PDSB) with a “buy” rating and $7 price target. The stock closed at $3.05 on Nov. 4. PDS is developing anti-cancer therapeutics leveraging its proprietary...
William Blair upgraded Sientra (NASDAQ:SIEN) to “outperform,” saying the company’s near-to-midterm outlook has stabilized and is improving. The stock closed at $6.77 on Nov. 4. Analyst Margaret Kaczor writes that she...
H.C. Wainwright launched coverage of aTyr Pharma (NASDAQ:LIFE) with a “buy” rating and $8 price target. The stock closed at $3.73 on Nov. 4. aTyr is developing therapies leveraging resokines, naturally occurring...
Dawson James Securities initiated coverage of CollPlant Biotechnologies (NASDAQ:CLGN) with a “buy” rating and $9 price target. The stock closed at $4.62 on Nov. 1. CollPlant’s technology platform mass produces...
William Blair upgraded Agile Therapeutics (NASDAQ:AGRX) to “outperform” after an FDA advisory committee voted overwhelmingly to approve its resubmitted NDA for the Twirla transdermal combined hormonal contraceptive...
Oyster Point Pharma (NASDAQ:OYST) priced an initial public offering of five million common shares at a price of $16 each to raise gross proceeds of $80-million. The offering is expected to close on Nov. 4. The company...
Echelon Wealth Partners launched coverage of IntelGenx (TSXV:IGX; OTCQX:IGXT) with a “speculative buy” rating and price target of $1.60 (Canadian). The stock closed at 73 cents on Oct. 29. The firm’s flagship...
SVB Leerink upgraded Deciphera Pharmaceuticals (NASDAQ:DCPH) to “market perform” from “underperform” and raised its price target to $34 from $29 after the FDA decided to split competitor Blueprint Medicines’ NDA...
Profound Medical’s (TSX:PRN; OTCQX:PRFMD) common shares have been certified for listing on The Nasdaq Stock Market, with trading slated to begin on Oct. 29 under the stock symbol “PROF.” The company’s common...
H.C. Wainwright launched coverage of Ekso Bionics Holdings (NASDAQ:EKSO) with a “buy” rating and $1.20 price target. The stock closed at 59 cents on Oct. 25. Ekso Bionics develops and markets robotic exoskeletons for...